AN2 Therapeutics Inc
Research AN2 Therapeutics Inc (ANTX) on Bullrun: market cap USD 159.76M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerANTX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 159.76M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 8.19M
- Free cash flow-USD 7.00M
Valuation Snapshot
latest market cap is USD 159.76M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 35.17M | -USD 29.83M | n/a | -1.16 | USD 19.94M | n/a | USD 53.06M |
| FY2024 | USD 0 | -USD 51.32M | -USD 49.26M | n/a | -1.72 | USD 21.35M | n/a | USD 81.85M |
| FY2023 | USD 0 | -USD 64.73M | -USD 53.29M | n/a | -2.74 | USD 15.65M | USD 0 | USD 124.70M |
| FY2022 | USD 0 | -USD 40.96M | -USD 33.46M | n/a | -2.79 | USD 27.22M | USD 53.00K | USD 95.37M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 159.76M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 31.25M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 41.29M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 609.40M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 184.91M | n/a | n/a | n/a |
About AN2 Therapeutics Inc
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is AN2 Therapeutics Inc's market cap?
AN2 Therapeutics Inc's market capitalization is USD 159.76M.
What does AN2 Therapeutics Inc do?
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.